Alzheimer’s diagnose Leverage Optina’s FDA Breakthrough designation for Alzheimer’s testing to position a joint solution with memory clinics and neurology centers, targeting early detection programs and dementia care pathways.

Eye and brain Promote cross-selling opportunities linking retinal deep phenotyping with neurology and geriatrics services to identify patients at risk for Alzheimer’s and systemic conditions, expanding into integrated screening programs.

Clinical partnerships Capitalize on active collaborations and in-community access programs to establish pilot projects with ophthalmology, retina centers, and aging care networks to demonstrate real-world efficacy and drive adoption.

Regulatory readiness Highlight FDA clearance and Health Canada licensing to reassure large health systems and payer organizations about regulatory maturity, enabling faster procurement and reimbursement discussions.

Funding signals Align outreach with Optina’s strong funding background and venture interest to support co-developed contracts, research collaborations, and sponsored trials in memory loss, AMD, and cardiovascular insights.